Know Labs Announces Significant Pre-Clinical Progress of UBAND Non-Invasive Continuous Glucose Monitor

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – a creator of innovative medical diagnostic solutions, today announced significant progress in the development of its wearable UBAND non-invasive Continuous Glucose Monitor (CGM). Increased accuracy and precision in laboratory test subject measurements have allowed the Company to expedite its focus on an FDA-approved CGM, causing it to curtail plans for its previously announced calorie counter product for the consumer market.

Dr. James “Andy” Anderson, M.D., Know Labs Chief Medical Officer, stated, “The UBAND CGM will be submitted for review under the FDA’s De Novo pathway. There is nothing else like it in the continuous glucose monitoring market, nor in the broader medical diagnostic world. Our Advisory Board of world class experts in diabetes care will bring together prominent investigators from around the country for clinical trials of this unique product.”

Dr. Anderson expressed his enthusiasm for recent developments at the Company in a video released today. Here is a link to that video:

“An FDA-approved wearable non-invasive CGM has always been our goal. It will revolutionize lifestyle management for people with diabetes and those at significant risk for developing this pandemic disease. We initially believed our first product would be a wearable calorie counter for the consumer market,” said Know Labs, Inc. CEO Phil Bosua. “At this point we have seen such dramatic progress in the lab we can now go straight for that ultimate goal and reach the large global market of people with diabetes allowing them to continuously monitor their blood glucose without the need for finger sticks or needles for the insertion of filaments or sensors. The truly non-invasive device and lower costs will also make the UBAND CGM ideal for individuals with pre-diabetes who are trying to modify their lifestyle by diet and exercise. Our dream of creating a wearable FDA-approved non-invasive CGM is just around the corner.”

The unique technology at Know Labs is based upon a strong intellectual property foundation. Mark Tapsak, Ph.D., formerly a system designer for CGM developer Dexcom, recently joined the Company as Vice President for Intellectual Property, charged with expanding and fortifying the Know Labs IP portfolio.

Know Labs’ move to build its wearable UBAND CGM for its FDA De Novo clinical trials is supported by its manufacturing partner Racer Technology, a global medical device and wearables manufacturer.

“We are curtailing any activities that take our focus away from the CGM,” said Company Chairman and Founder Ron Erickson. “We believe we are on the cusp of bringing to market the holy grail of the medical diagnostics industry. We are full speed ahead on our clinical path.”

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at

Safe Harbor Statement

This video at the link above and this release contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2018, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Know Labs, Inc.
Jordyn Theisen
Ph. 319-321-8470

Source: Know Labs, Inc.